Literature DB >> 32732241

The use of tocilizumab and tofacitinib in patients with resolved hepatitis B infection: a case series.

Naomi Serling-Boyd1, Amir M Mohareb2, Arthur Y Kim2, Emily P Hyle2, Zachary S Wallace3.   

Abstract

Entities:  

Keywords:  cytokines; immune system diseases; therapeutics

Mesh：

Substances：

Year:  2020        PMID： 32732241      PMCID： PMC7855328          DOI： 10.1136/annrheumdis-2020-218289

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  6 in total

1.  Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

Authors:  Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong
Journal:  Hepatology       Date:  2018-04       Impact factor: 17.425

Review 2.  American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy.

Authors:  Robert P Perrillo; Robert Gish; Yngve T Falck-Ytter
Journal:  Gastroenterology       Date:  2014-10-31       Impact factor: 22.682

Review 3.  Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.

Authors:  Ying-Ming Chiu; Der-Yuan Chen
Journal:  Expert Rev Clin Immunol       Date:  2020-01-11       Impact factor: 4.473

Review 4.  Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.

Authors:  Sonali Paul; Aaron Dickstein; Akriti Saxena; Norma Terrin; Kathleen Viveiros; Ethan M Balk; John B Wong
Journal:  Hepatology       Date:  2017-06-22       Impact factor: 17.425

5.  Calculating the benefits of a Research Patient Data Repository.

Authors:  Ruth Nalichowski; Diane Keogh; Henry C Chueh; Shawn N Murphy
Journal:  AMIA Annu Symp Proc       Date:  2006

6.  Predictors of hepatitis B and C virus reactivation in patients with psoriasis treated with biologic agents: a 9-year multicenter cohort study.

Authors:  Hsien-Yi Chiu; Ying-Ming Chiu; Nien-Feng Chang Liao; Ching-Chi Chi; Tsen-Fang Tsai; Chang-Yu Hsieh; Tsu-Yi Hsieh; Kuo-Lung Lai; Tsu-Man Chiu; Nan-Lin Wu; Rosaline Chung-Yee Hui; Chaw-Ning Lee; Ting-Shun Wang; Po-Hua Chen; Chao-Chun Yang; Yu-Huei Huang
Journal:  J Am Acad Dermatol       Date:  2019-12-09       Impact factor: 11.527
  6 in total
  5 in total

1.  Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study.

Authors:  Wenxin Zhang; Xiangqian Li; Baifu Chen; Jianzhong Zhang; Kara Melissa T Torres-Culala; Cheng Zhou
Journal:  Front Med (Lausanne)       Date:  2022-06-21

Review 2.  Management of hepatitis B virus reactivation due to treatment of COVID-19.

Authors:  Terry Cheuk-Fung Yip; Madeleine Gill; Grace Lai-Hung Wong; Ken Liu
Journal:  Hepatol Int       Date:  2022-03-02       Impact factor: 9.029

3.  Screening for Hepatitis B Virus Prior to Initiating Tocilizumab and Tofacitinib in Patients With Rheumatic Diseases: A Cross-sectional Study.

Authors:  Amir M Mohareb; Naomi J Patel; Xiaoqing Fu; Arthur Y Kim; Zachary S Wallace; Emily P Hyle
Journal:  J Rheumatol       Date:  2021-08-01       Impact factor: 4.666

4.  Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis Patients Undergoing Tocilizumab-Containing Treatment.

Authors:  Meng Hsuan Kuo; Chih-Wei Tseng; Ming-Chi Lu; Chien-Hsueh Tung; Kuo-Chih Tseng; Kuang-Yung Huang; Chi-Hui Lee; Ning-Sheng Lai
Journal:  Dig Dis Sci       Date:  2021-01-02       Impact factor: 3.199

Review 5.  Risk of hepatitis B virus reactivation in patients with autoimmune diseases undergoing non-tumor necrosis factor-targeted biologics.

Authors:  Shintaro Akiyama; Thomas G Cotter; Atsushi Sakuraba
Journal:  World J Gastroenterol       Date:  2021-05-21       Impact factor: 5.742
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.